ME
DNA icon

McIlrath & Eck’s Ginkgo Bioworks DNA Stock Holding History

McIlrath & Eck’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$458 – 962
2024
Q1 		$458 Buy
+10
New +$518 ﹤0.01% 896
2023
Q4 		– Sell
-10
Closed -$715 – 930
2023
Q3 		$715 Hold
10
– – ﹤0.01% 832
2023
Q2 		$735 Hold
10
– – ﹤0.01% 839
2023
Q1 		$525 Hold
10
– – ﹤0.01% 874
2022
Q4 		$668 Buy
10
+1
+11% +$92 ﹤0.01% 818
2022
Q3 		$1K Hold
9
– – ﹤0.01% 794
2022
Q2 		$1K Hold
9
– – ﹤0.01% 769
2022
Q1 		$1K Hold
9
– – ﹤0.01% 760
2021
Q4 		$3K Hold
9
– – ﹤0.01% 689
2021
Q3 		$4K Buy
+9
New +$4.38K ﹤0.01% 641

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

McIlrath & Eck's DNA Position: Q2 2024 in Review

McIlrath & Eck sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 10 shares — an estimated $458 sold.

McIlrath & Eck first reported a position in DNA in Q3 2021 and held it in 10 quarters. The position peaked at $4K in Q3 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • McIlrath & Eck reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • McIlrath & Eck sold 10 Ginkgo Bioworks shares in Q2 2024, an estimated $458.
  • McIlrath & Eck first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 10 quarters.
  • McIlrath & Eck's Ginkgo Bioworks position peaked at $4K in Q3 2021.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on McIlrath & Eck's 13F filing for Q2 2024, filed 14 Aug 2024.